Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Grim turned golden?
7 million?
So what is Anavex worth if they have similar, less than stellar, results? Where is the bar exactly?
Exactly, so what was the scam? Who benefitted?
The argument that the quick drop from $14 supports the claim that Anavex is a scam is unreasonable.
For those of you wondering how the "pump" went bad at $14 (I can't PM)...
People claiming the company is a scam because the share price rose to $14 and is now below $3 need to consider who benefited from such a change in the share price. Were there any shares issued prior to the dump, or sold during the dump? Additionally, from my vague recollection over 2x the float traded in a very short time period. How many were naked shorts?
If the company were a scam, where did the money flow? This would be fairly easy to figure out with an SEC investigation.
I would also not count out a short and distort scheme. Anyone shorting the stock would have had substantial gains from "pumping" the stock before shorting.
The worst thing about that event is that most of the actual value was sucked out of the share price. With this I mean almost half of the valuation of the company was sucked out in cash and put in someone's pocket.
Given the company continues to sink cash into clinical trials and we have (slowly) been getting encouraging results, I don't know how someone can call this company a scam without evidence of such a claim. That would be easy to support.
Certainly there are other players in the market that could have caused such a swing in price. Calling the company a scam without supporting evidence is questionable.
What does Billy Baroo think about this:Billy Baroo?
Graphical summary of the model of Aß pathology in GRU102.
Graphical Summary
Pan-neuronal Aß expression leads to an imbalance between reactive oxygen species (ROS) production and antioxidant (AOX) defense, resulting in oxidative stress as an early event in GRU102. Increase in mitochondrial protein carbonyl content (mtPCC) was also observed as an early phenomenon in GRU102. Elevated oxidative stress further affects ROS-sensitive Tricarboxylic Acid (TCA) cycle enzyme, including alpha-ketoglutarate dehydrogenase (aKGDH), resulting in a reduction of its activity as well as altered levels of TCA metabolites (aKGDH, fumarate and malate) in old GRU102. Together with the reduction in electron transfer chain (ETC) complex I and IV activities as well as low ATP levels in the GRU102 animals we reported previously (Fong et al., 2016), these phenomena result in metabolic stress. Proteostasis, an energy-intensive process, is impaired by metabolic and oxidative stress, resulting in an increase in general protein aggregates. Treatment with Metformin (Met) increases stress resistance and rescues metabolic defects of GRU102. Metformin-treated GRU102 also appears to reduce the increase in protein aggregates in GRU102, even though it could not fully rescue this phenotype.
https://doi.org/10.7554/eLife.50069.025
Didn't someone ask about oxidative stress?
And that is the effect of short sellers on start-ups; artificially depressing share price and valuation of an organization so that available high risk funding dilutes at an accelerated rate. It should be illegal.
Missling didn't turn off the mike, he dropped it and it broke to the sound of crickets. If you want to be a rockstar you have to play some rock-n-roll. Hopefully, next time he brings an electric guitar. In the meantime I hope he is not getting paid like a rockstar...
That would be amazing if it would treat 100%. Personally from the small open label 2A trial, I would not expect that A2-73 could treat the entire AD population. It does appear that a decent percentage of the AD population could benefit, making A2-73 marketable. The purpose of a precision medicine approach was to identify a target population that would benefit, and leading to successful trials along the way. Identifying a benefit to even a quarter of the AD population would be a win. It may be the unrealistic side of the antagonist as well that would expect that a marketable drug would have to apply to the whole AD population, but that is for someone else to figure out.
Oh, yes, like all the other AD drug trials. If BP states it will work, it must be so.
This doesn't make sense. Who is claiming it will treat everyone? Did Anavex state that?
Why would they do that? Dosing has been calculated precisely; that's why it is called precision medicine.
Gobble, gobble...
Biogen could not cough up enough money after finding out how well it worked with MS. It would have been the largest contract ever for a small $40 billion market...
I was thinking more like cheesecake...
I wonder why they decided on participants over 18? Is there possibly something else they could be looking for? Could be right there, like a snake in the grass.
What competition?
Possibly... we'll just have to wait and see.
Pre-market bid now $3.16. What was the relevance again?
Sorry, failing to find the relevance. Is this another opinion?
Sorry, failing to find the relationship here.
Usually takes money to make money. I suppose in an ideal world a company would not pay for clinical trials or operating expenses... How much has big pharma spent on clinical trials for alzheimers?
$3.84 ask
The quote on the bottom of your post is priceless! Thanks for your opinion.
Anavex is pretty good at selecting super responders aren't they. What are the odds that every trial they do with a small sample size results in a positive outcome? Oh yeah, it is placebo effect...
Compare parkinsons to alzheimers safety trial. What are your concerns?
Are you swing trading... there may not be a cabal.
How long does LPC have to hold the shares and do they purchase at a discount? It seems reasonable that LPC could have sold shares that were sold to them under the agreement.
Well I tried for 4,000 at $3.25 a little after lunch, but it never came back down.
The stakes are getting higher the further we progress and get closer to AD trial completion. More people will take a small position and hold just for the chance of success without the hassle of swing trades. The repeated failures of other companies have unreasonably suppressed Anavex's valuation and any indication we could get approval and this thing will launch. I think the share price has started an upward trend to AD readout with swings around other news. My expectations are that this Friday will not knock it out of the park. My timeline for the $4 zone is by mid-October, but my estimations on timeframes haven't exactly been spot on. My price targets have been somewhat in the ballpark, and enough to make a profit. Sometimes I could have made more money with other investments waiting for the price to get there though. I dont think we will see below $3 again unless we recieve bad news.
Similar target zone: $3.95-$4.09. Let's get there!
Awesome!
Definately once a successful human trial is completed. The mouse model itself is a shot at what may represent a human subject. They change all of the time because they often don't match. The mouse models are different for each target, success in one does not translate to success in another. To date the models have not been a sufficient indication of trial success. Once they find a "good" target maybe maybe they can make a more representative model so advancements will accelerate.
Anavex is advancing. Yay.
I agree with you. I am encouraged with the trial results so far; just cautious in how I use the information to date. Human trials will give us the answer we have been waiting for. I'm looking for success in whatever form it comes in the human trials. Mouse data to me is like an entry fee, it does not give us an indication of how well we will perform, only that we are one of the players.
Mouse models don't always translate to human subjects. Too many failed clinical trials to support this point.
Wind, wind, wind
Haven't they been asking for volunteers for quite a while now? Wouldn't they have a reasonable estimate of how many patients would be readily available? Why 69?
Come on, no one gripping because of a trial with children? Wasn't ther alot of mumbo jumbo about the Rhett trial with adults?
Ok, I like your thinking better. Should have a better idea of when we can get there this year.